专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004098589A8 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES 审中-公开
标题翻译： 4-溴 - 5-（2-氯代苯甲酰氨基） - 1H-吡唑-3-羧酸酰胺衍生物及相关化合物作为治疗炎症性疾病的BRADYKININ B1受体拮抗剂
公开(公告)号：WO2004098589A8
公开(公告)日：2005-12-08
申请号：PCT/US2004013219
申请日：2004-04-30
申请人： ELAN PHARM INC , TUNG JAY S , GAROFALO ALBERT W , PLEISS MICHAEL A , WU JING , WONE DAVID W G , GUINN ASHLEY C , DRESSEN DARREN B , NEITZ R JEFFREY , MARUGG JENNIFER , NEITZEL MARTIN
发明人： TUNG JAY S , GAROFALO ALBERT W , PLEISS MICHAEL A , WU JING , WONE DAVID W G , GUINN ASHLEY C , DRESSEN DARREN B , NEITZ R JEFFREY , MARUGG JENNIFER , NEITZEL MARTIN
IPC分类号： A61P29/00 , C07D231/16 , C07D231/40 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D487/08 , A61K31/415 , A61K31/4155
CPC分类号： C07D401/14 , C07D231/16 , C07D231/40 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D487/08
摘要： Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
摘要翻译：公开了作为缓激肽B1受体拮抗剂的式I和II化合物，可用于治疗由缓激肽B1受体介导的哺乳动物中疾病或与疾病相关的不良症状。某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。

2. 发明申请

WO2004098590A8 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES 审中-公开
标题翻译： 4-溴-5-（2-氯苯甲酰氨基）-1H-吡唑-3-羧酸（1-（氨基羰基）ETH-1-YL）酰胺衍生物及相关化合物作为治疗炎症性疾病的BRADYKININ B1受体拮抗剂
公开(公告)号：WO2004098590A8
公开(公告)日：2005-12-15
申请号：PCT/US2004013400
申请日：2004-04-30
申请人： ELAN PHARM INC , TUNG JAY S , GAROFALO ALBERT W , PLEISS MICHAEL A , WU JING , WONE DAVID W G , GUINN ASHLEY C , DRESSEN DARREN B , MARUGG JENNIFER , NEITZEL MARTIN
发明人： TUNG JAY S , GAROFALO ALBERT W , PLEISS MICHAEL A , WU JING , WONE DAVID W G , GUINN ASHLEY C , DRESSEN DARREN B , MARUGG JENNIFER , NEITZEL MARTIN
IPC分类号： A61P29/00 , C07D231/16 , C07D231/40 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D487/08 , A61K31/415 , A61K31/4155
CPC分类号： C07D401/14 , C07D231/16 , C07D231/40 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D487/08
摘要： Disclosed are compounds of formulae (I) and (II) that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action. Wherein Z is selected from O, S and NH; Q of formula (III) and the other substituents are as defined in claim 1.
摘要翻译：公开了缓激肽B1受体拮抗剂的式（I）和（II）化合物，并且可用于治疗由缓激肽B1受体介导的哺乳动物中疾病或与疾病相关的不良症状。某些化合物表现出更高的效力，并且还预期表现出增加的作用持续时间。其中Z选自O，S和NH; 式（III）的Q和其它取代基如权利要求1中所定义。

3. 发明申请

WO2005090296A3 N-SUBSTITUTED BENZENE SULFONAMIDES 审中-公开
标题翻译： N-取代苯甲磺酰胺
公开(公告)号：WO2005090296A3
公开(公告)日：2005-11-24
申请号：PCT/US2005007811
申请日：2005-03-11
申请人： ELAN PHARM INC , NEITZEL MARTIN , MARUGG JENNIFER
发明人： NEITZEL MARTIN , MARUGG JENNIFER
IPC分类号： A61K31/185 , A61K31/4172 , A61K31/426 , A61K31/445 , C07C311/15 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/19 , C07C311/20 , C07C311/21 , C07C311/31 , C07C311/51 , C07C317/32 , C07D209/14 , C07D211/58 , C07D231/06 , C07D277/24 , C07D307/52 , C07D307/81 , A61K31/18 , A61P25/28
CPC分类号： C07D277/24 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/19 , C07C311/20 , C07C311/21 , C07C311/51 , C07C317/32 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/10 , C07C2602/42 , C07D209/14 , C07D211/58 , C07D231/06 , C07D307/52 , C07D307/81
摘要： The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R1, R2, R3, R4, and R3, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula (I).
摘要翻译：本发明提供用于治疗或预防认知障碍（例如阿尔茨海默病）的N-取代苯磺酰胺。特别感兴趣的化合物由式（I）定义，其中R 1，R 2，R 3，R 4和R 3如说明书中所述。本发明还包括含有式（I）化合物的药物组合物以及使用式（I）化合物治疗认知障碍（包括阿尔茨海默氏病）的方法。

4. 发明申请

WO2004099155A3 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES 审中-公开
标题翻译： 4-溴-5-（2-氯 - 苯甲酰氨基）-1H-吡唑-3-羧酸（苯）酰胺衍生物及相关化合物作为治疗炎症性疾病的BRADYKININ B1受体拮抗剂
公开(公告)号：WO2004099155A3
公开(公告)日：2005-11-10
申请号：PCT/US2004013655
申请日：2004-04-30
申请人： ELAN PHARM INC , GAROFALO ALBERT W , TUNG JAY S , PLEISS MICHAEL A , WU JING , WONE DAVID W G , GUINN ASHLEY C , DRESSEN DARREN B , MARUGG JENNIFER , NEITZEL MARTIN
发明人： GAROFALO ALBERT W , TUNG JAY S , PLEISS MICHAEL A , WU JING , WONE DAVID W G , GUINN ASHLEY C , DRESSEN DARREN B , MARUGG JENNIFER , NEITZEL MARTIN
IPC分类号： A61K31/4152 , A61K31/416 , C07D231/16 , C07D231/40 , C07D401/12 , C07D403/12 , C07D417/12 , A61K31/415 , A61K31/4155 , A61P29/00
CPC分类号： C07D401/12 , C07D231/16 , C07D231/40 , C07D403/12 , C07D417/12
摘要： Disclosed are compounds that are bradykinin B1 receptor antagonists of formulae (I) and (II) and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action. Formula (I) and (II) wherein Z' is selected from O, S and NH; R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; R is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R is selected from the group consisting of hydrogen, alkyl, and substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; R is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; R is selected from the group consisting of hydrogen, alkyl and substituted alkyl; X is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, carboxyl, carboxyl esters, cyano, halo, heteroaryl, substituted heteroaryl, hydroxy, nitro, amino, substituted amino, acylamino, and aminoacyl.
摘要翻译：公开了作为式（I）和（II）的缓激肽B1受体拮抗剂的化合物，可用于治疗由缓激肽B1受体介导的哺乳动物中疾病或与疾病相关的不良症状。某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。式（I）和（II）其中Z'选自O，S和NH; R 1选自氢，烷基，取代的烷基，烯基，取代的烯基，炔基，取代的炔基，芳基，取代的芳基，环烷基，取代的环烷基，杂芳基，取代杂芳基，杂环和取代的杂环; R 2选自氢，烷基和取代的烷基; R 3选自氢，烷基和取代的烷基，烯基，取代的烯基，炔基，取代的炔基，芳基，取代的芳基，环烷基，取代的环烷基，杂芳基，取代的杂芳基，杂环和取代的杂环; R 4选自芳基，取代的芳基，杂芳基和取代的杂芳基; R 5选自氢，烷基和取代的烷基; 氰基，卤素，杂芳基，取代的杂芳基，羟基，硝基，氨基，取代的氨基，酰基氨基，氨基，取代的烷基，取代的烷基，和氨酰基。

5. 发明申请

WO2006078753A1 N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES 审中-公开
标题翻译： N-取代的杂环磺酰胺
公开(公告)号：WO2006078753A1
公开(公告)日：2006-07-27
申请号：PCT/US2006001792
申请日：2006-01-18
申请人： ELAN PHARM INC , NEITZEL MARTIN
发明人： NEITZEL MARTIN
IPC分类号： C07D403/12 , A61K31/55 , A61P25/28 , C07D223/12 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
CPC分类号： C07D413/12 , C07D223/12 , C07D401/12 , C07D403/12 , C07D409/12 , C07D417/12
摘要： The invention provides N-substituted heterocyclic-sulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R 1 , R 2 , Z and n are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).
摘要翻译：本发明提供了用于治疗或预防认知障碍（例如阿尔茨海默病）的N-取代的杂环磺酰胺。特别感兴趣的化合物由式（I）定义，其中R 1，R 2，Z和n如说明书中所述。本发明还包括含有式（I）化合物的药物组合物以及使用式（I）化合物治疗认知障碍的方法。

6. 发明专利

GB1276625A IMPROVEMENTS IN OR RELATING TO ROTARY POURING VALVES FOR VESSELS CONTAINING MOLTEN METAL 未知
公开(公告)号：GB1276625A
公开(公告)日：1972-06-07
申请号：GB670170
申请日：1970-02-11
申请人： NEITZEL MARTIN
发明人： NEITZEL MARTIN
IPC分类号： B22D41/26
摘要： 1276625 Valves M NEITZEL 11 Feb 1970 [28 Feb 1969] 6701/70 Heading F2V A valve for a vessel holding molten metal comprises a stationary disc-shaped member 6 having at least one flow opening therein, one face of the disc being in rotary sliding engagement with an adjacent face of a rotatable valve member 9 through which extends at least one passage capable of being moved into and out of register with the or each opening in the disc, the disc 6 being thin in relation to the rotary valve member 9 and having a higher thermal conductivity. The sliding surfaces are lubricated by tar exuding from pores in the members 6 and 9 and they are held together by a thrust ring 14 bearing on an actuator ring 10. The actuator ring 10 is formed as a gear-ring and is driven by two parallel racks 11. The disc member 6 makes direct contact with the high temperature region of the melt so that, together with the thickness of section of the disc 6 relative to the member 9, the temperature of the sliding face V is 80% of that of the metal when pouring. In order to prevent the melt entering the initially cold vessel from solidifying in the region of the fixed disc 6, a powder mass which reacts exothermically to a minimum temperature is filled into the passages of the disc 6. The passages of the valve are lined with metal-ceramic or liquid cast materials having a high grade surface quality to prevent wetting.

7. 发明专利

DE602004016992D1 未知
公开(公告)号：DE602004016992D1
公开(公告)日：2008-11-20
申请号：DE602004016992
申请日：2004-04-30
申请人： ELAN PHARM INC
发明人： TUNG JAY S , GAROFALO ALBERT W , PLEISS MICHAEL A , WU JING , WONE DAVID W , GUINN ASHLEY C , DRESSEN DARREN B , NEITZ R JEFFREY , MARUGG JENNIFER , NEITZEL MARTIN
IPC分类号： A61K31/415 , A61K31/4155 , A61P29/00 , C07D231/16 , C07D231/40 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D487/08

8. 发明专利

CA2524318A1 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTORANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES 未知
公开(公告)号：CA2524318A1
公开(公告)日：2004-11-18
申请号：CA2524318
申请日：2004-04-30
申请人： ELAN PHARM INC
发明人： TUNG JAY S , GAROFALO ALBERT W , MARUGG JENNIFER , WU JING , PLEISS MICHAEL A , NEITZEL MARTIN , WONE DAVID W G , GUINN ASHLEY C , DRESSEN DARREN B
IPC分类号： C07D231/40 , A61K31/415 , A61K31/4152 , A61K31/4155 , A61K31/416 , A61P29/00 , C07D231/16 , C07D401/12 , C07D403/12 , C07D417/12
摘要： Disclosed are compounds that are bradykinin B1 receptor antagonists of formulae (I) and (II) and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency a nd are also expected to exhibit increased duration of action. Formula (I) and (II) wherein Z~ is selected from O, S and NH; R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; R2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; R4 is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; R5 is selected fro m the group consisting of hydrogen, alkyl and substituted alkyl; X is selected from the group consisting of hydrogen,alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, carboxyl, carboxyl esters, cyano , halo, heteroaryl, substituted heteroaryl, hydroxy, nitro, amino, substituted amino, acylamino, and aminoacyl.

9. 发明专利

CA2559047A1 N-SUBSTITUTED BENZENE SULFONAMIDES 未知
公开(公告)号：CA2559047A1
公开(公告)日：2005-09-29
申请号：CA2559047
申请日：2005-03-11
申请人： ELAN PHARM INC
发明人： NEITZEL MARTIN , MARUGG JENNIFER
IPC分类号： C07C311/15 , A61K31/18 , A61K31/185 , A61K31/4172 , A61K31/426 , A61K31/445 , A61P25/28 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/19 , C07C311/20 , C07C311/21 , C07C311/31 , C07C311/51 , C07C317/32 , C07D209/14 , C07D211/58 , C07D231/06 , C07D277/24 , C07D307/52 , C07D307/81

10. 发明专利

CA2524274A1 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS ASBRADYKININ B1 RECEPTOR ANTAGONISTS FOR THETREATMENT OF INFLAMMATORY DISEASES 未知
公开(公告)号：CA2524274A1
公开(公告)日：2004-11-18
申请号：CA2524274
申请日：2004-04-30
申请人： ELAN PHARM INC
发明人： GUINN ASHLEY C , WU JING , WONE DAVID W G , NEITZEL MARTIN , PLEISS MICHAEL A , GAROFALO ALBERT W , TUNG JAY S , DRESSEN DARREN B , MARUGG JENNIFER
IPC分类号： A61K31/415 , A61K31/4155 , A61P29/00 , C07D231/16 , C07D231/40 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D487/08
摘要： Disclosed are compounds of formulae (I) and (II) that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency a nd are also expected to exhibit increased duration of action. Wherein Z is selected from O, S and NH; Q of formula (III) and the other substituents are as defined in claim 1.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式